utilises the most advanced technology (WGS), professional expertise in big data analysis, and an AI approach combined with clinical information to dramatically improve patient stratification for a variety of molecular therapies.
The most powerful
biomarker discovery platform
GEMMAai™
GEnoMic Marker Analyzer
AI-Powered platform for matching patients with right treatment
Most clinical trials fail
Most cancer treatmens have low efficacy
GEMMAai™ PLATFORM
How do we do it?
Our platform was created to base medical decisions on individual patient characteristics, rather than on standard treatment guidelines. Its key strengths lie in whole-genome sequencing,clinical data implementation, the AI , and the expertise. GEMMAai is continuously developed by leading experts in the field, from specialists in AI to experienced genomic scientists, who supervise the feature extraction process to ensure the most relevant biological context.
Learn how we do it.
Our proprietary software
for data mining
5410
whole-genome sequence data
153
genomic paterns (features)
9
AI-powered assays
Our pipeline
Our AI-powered methodology can be used to build a model for any drug-response diagnostic tool, including PARP, CDK4/6 and mTOR inhibitors. Since AI can continuously learn from real-world genomic data, using our engine on larger patient cohorts will help us to identify new genomic patterns to build more accurate prediction models for any targeted therapy.
TUMOR
TYPE
WGS DATA
TARGETED THERAPY
DISCOVERY
PROTOTYPE ASSAY
ANALITYCAL VALIDATION
CLINICAL VALIDATION
REGULATORY APPROVAL
UPCOMING
MILESTONES
OVARIAN
512
Carboplatin / PARPi
FDA breakthrough device in Q3 2021
BREAST
2152
PARPi
CDK4/6i
Ant-HER2
mTORi
PIK3i
2 analytically validated diagnostic tools in Q1 2021
LUNG
1852
PARPi
immunotherapy
2 prototype assays in Q3 2021
FASETM
GENOMIC FEATURE DATABASE
YOUR inhibitor
Discovery and validation
AI-POWERED
STRATIFICATION DIAGNOSTIC TOOL
TUMOR TYPE: OVARIAN
WGS DATA
512
TARGETTED THERAPY
UPCOMING MILESTONES
FDA breakthrough device in Q3 2021
TUMOR TYPE: BREAST
WGS DATA
2152
TARGETTED THERAPY
UPCOMING MILESTONES
2 analytically validated diagnostic tools in Q1 2021
TUMOR TYPE: LUNG
WGS DATA
1852
TARGETTED THERAPY
UPCOMING MILESTONES
2 prototype assays in Q3 2021
FUSETM
WGS DATA
GENOMIC FEATURE DATABASE
TARGETTED THERAPY
YOUR inhibitor
DISCOVERY AND VALIDATION
AI-POWERED STRATIFICATION DIAGNOSTIC TOOL
Individual "Decision Tree" Construction
Random Forest Artificial Intelligence methodology based on Training Dataset
INSTEAD OF >1 000 SAMPLES, GEMMAaiTM
requires only 100 training data for a reliable output and achieves the optimal balance of sensitivity (recall) and precision.
Discrimination threshold
Learning curves
CARBOPLATIN/PARPi CLASSIFIER
_ALICE
ArtificiaL Intelligence ClassifiEr
NEW GLOBAL STANDARD IN OVARIAN ONCOLOGY THROUGH CONNECTING AI TECHNOLOGY TO WHOLE-GENOME DATA
Our proprietary software
for data mining
_ALICE is a Random Forest model, consisting of 100 decision trees. It analyses 44 genomic features associated with ovarian cancer treatment response. Apart from ‘gold standard’ biomarkers for HRD like BRCA1/2 mutations, deletions with microhomologies and tandem duplications, we have identified 3 novel biomarkers correlated with HRD and 22 important genomic biomarkers associated with PARPi clinical response.
Biomarker imporance
3
novel biomarkers correlated with HRD
22
novel important genomic biomarkers associated with PARPi clinical response
19
‘gold standard’ biomarkers
_ALICE tech note
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque non sodales massa, sit amet venenatis diam. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Etiam a imperdiet nulla.
Download Tech Note
